pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,063 catalysts · 5,063 phase readout · 2,308 8k filing · 316 pdufa · 271 earnings · 108 phase 2 completion · 50 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: phase readout×clear all
type
  • phase readout5,063
  • 8k filing2,308
  • pdufa316
  • earnings271
  • phase 2 completion108
  • phase 1 completion50
phase 1 2 completion
28
  • phase 1 initiation22
  • phase 0 trial completion21
  • phase 1 2 initiation9
  • therapy area

    no tagged catalysts yet

    Date TBD

    50
    ›NOT_YET_RECRUITINGphase readoutNCT06855043: Little Lungs Study

    Sponsor: University of Wisconsin, Madison. Phase: PHASE1. Conditions: Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05274243: 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis

    Sponsor: Vanderbilt University Medical Center. Phase: PHASE2. Conditions: Rheumatoid Arthritis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT00200343: Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

    Sponsor: Tanabe Pharma Corporation. Phase: PHASE3. Conditions: Chronic Hepatitis C

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06722508: Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients

    Sponsor: University of California, Davis. Phase: NA. Conditions: Head Cancer, Neck Cancer, Sarcopenia, Head and Neck Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07484308: Application and Impact Assessment of Ultrasound Super-Resolution Blood Flow Imaging (URM) in Patients With Renal Failure

    Sponsor: Ma Zhe. Phase: NA. Conditions: Kidney Failure

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06331325: Comparison of Frenotomy and Frenectomy Techniques for Management of High Frenum Attachment in Adults

    Sponsor: October University for Modern Sciences and Arts. Phase: NA. Conditions: High Frenum Attachment

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06649825: Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.

    Sponsor: Shanghai Zhongshan Hospital. Phase: NA. Conditions: Familial Adenomatous Polyposis (FAP)

    full page →ctgov ↗
    ›TEMPORARILY_NOT_AVAILABLEphase readoutNCT06169176: RAPA-501 Therapy of ALS Expanded Access Protocol

    Sponsor: Rapa Therapeutics LLC. Phase: . Conditions: Amyotrophic Lateral Sclerosis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07122089: Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

    Sponsor: Center Eugene Marquis. Phase: PHASE2. Conditions: Hepatocellular Carcinoma Non-resectable

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05024968: Sintilimab in Cancer of Unknown Primary

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Cancer of Unknown Primary Site

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04841668: Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly

    Sponsor: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta. Phase: . Conditions: Type 2 Diabetes Mellitus

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06768476: CART123 + Ruxolitinib in Relapsed/Refractory AML

    Sponsor: University of Pennsylvania. Phase: PHASE1. Conditions: Relapsed AML, Refractory AML

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07453576: Effect Of Different Sodium Hypochlorite Concentrations On Intracanal Substance P, CGRP And Opiorphin Levels And Postoperative Pain During Root Canal Retreatment

    Sponsor: KEZBAN MELTEM ÇOLAK. Phase: NA. Conditions: Persistent Apical Periodontitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07378618: Evaluation of the Accuracy of Palatal Orthodontic Miniscrew Placement.

    Sponsor: University of Roma La Sapienza. Phase: NA. Conditions: Malocclusion, Orthodontic Anchorage Procedures, Orthodontics

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07513974: Objective Measurement of the Mechanical Pain Threshold With an Algometer for Predicting Intraoperative Opioid Consumption in Patients Who Will be Operate by Thoracotomy and Sternotomy in Cardiac Surgery

    Sponsor: Université Libre de Bruxelles. Phase: NA. Conditions: Cardiac Surgery Subjects

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03741790: Airway Management of Pediatric Patients With Klippel-Feil Syndrome

    Sponsor: Boston Children's Hospital. Phase: . Conditions: Klippel-Feil Syndrome

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07424690: Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation

    Sponsor: Karolinska University Hospital. Phase: NA. Conditions: Atrial Fibrillation (AF), Atrial Fibrillation Ablation, Elderly

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05538910: Defining Neurobiological Links Between Substance Use and Mental Illness

    Sponsor: National Institute on Drug Abuse (NIDA). Phase: NA. Conditions: Major Depressive Disorder, Substance Use Disorder, Normal Physiology

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01820910: Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

    Sponsor: International Extranodal Lymphoma Study Group (IELSG). Phase: PHASE2. Conditions: Marginal Zone Lymphoma of Ocular Adnexal

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04196413: GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

    Sponsor: Stanford University. Phase: PHASE1. Conditions: Glioma of Spinal Cord, Glioma of Brainstem

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03044613: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

    Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase: PHASE1. Conditions: Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07228013: Examining Effects of Active Plant Engagement on College Student Well-Being and Performance

    Sponsor: Colorado State University. Phase: NA. Conditions: Perceived Stress, State Anxiety, Intrinsic Goal Orientation, Study Habits, Mood, Sleep Quality, Connectedness to Nature, Extrinsic Goal Orientation

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT01912313: Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)

    Sponsor: KU Leuven. Phase: NA. Conditions: IBS, Healthy

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02027233: Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults

    Sponsor: Institut National de la Santé Et de la Recherche Médicale, France. Phase: NA. Conditions: Severe Acute Respiratory Infection

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07469033: Prevalence of Misophonia in Turkish High School Students

    Sponsor: Ondokuz Mayıs University. Phase: . Conditions: Misophonia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07471958: Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

    Sponsor: Abramson Cancer Center at Penn Medicine. Phase: . Conditions: Cancer

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07403058: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction

    Sponsor: Axon Therapies, Inc.. Phase: NA. Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05830058: Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

    Sponsor: City of Hope Medical Center. Phase: PHASE2. Conditions: Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07430748: REGENFAST vs L-PRF in Periodontal Regeneration

    Sponsor: University of Santiago de Compostela. Phase: EARLY_PHASE1. Conditions: Regeneration, Periodontal Defects, Biomaterials

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02453048: Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine

    Sponsor: Institut National de la Santé Et de la Recherche Médicale, France. Phase: PHASE1. Conditions: Pertussis, Whooping Cough

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07299955: A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

    Sponsor: Biocon Biologics UK PLC. Phase: PHASE1. Conditions: Healthy Male Participants

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04926285: Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

    Sponsor: University of Illinois at Chicago. Phase: PHASE1. Conditions: Relapsed or Refractory Hematologic Malignancies

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07144085: Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

    Sponsor: Yi Tian. Phase: PHASE1. Conditions: Tumor, Metastatic Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04649385: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

    Sponsor: BeiGene. Phase: PHASE1. Conditions: Advanced Solid Tumor

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07557485: Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion

    Sponsor: Feng Gao. Phase: NA. Conditions: Vertebrobasilar Artery Occlusion, Endovascular Treatment

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04578938: Ketamine + Cognitive Training for Suicidality in the Medical Setting

    Sponsor: Rebecca Price. Phase: PHASE4. Conditions: Suicide, Attempted

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07558915: A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Sponsor: Genentech, Inc.. Phase: PHASE1. Conditions: Relapsed/Refractory Multiple Myeloma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07426315: Innovative Methodologies for Neuroplasticity in Developmental Age With the Use of Virtual Reality

    Sponsor: IRCCS Centro Neurolesi Bonino Pulejo. Phase: NA. Conditions: Neurodevelopmental Disorders

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04620915: Construal Level as a Novel Pathway for Affect Regulation and Cancer Control

    Sponsor: University of Oregon. Phase: NA. Conditions: Smoking Cessation, Smoking Reduction, Cancer

    full page →ctgov ↗
    ›WITHHELDphase readoutNCT06658015: [Trial of device that is not approved or cleared by the U.S. FDA]

    Sponsor: [Redacted]. Phase: . Conditions:

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05928325: Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment

    Sponsor: M.D. Anderson Cancer Center. Phase: NA. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06135740: Impact of Nutrition, Sleep, and Physical Activity on Intellectual Function and Muscle Mass in Older Adults

    Sponsor: Tokyo University. Phase: NA. Conditions: Cognition Disorders in Old Age, Cognitive Function, Frailty/Sarcopenia, MCI

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04089189: Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

    Sponsor: Impact Therapeutics, Inc.. Phase: PHASE2. Conditions: Ovarian Cancer

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07548489: Phenobarbital for Agitated Delirium

    Sponsor: Duke University. Phase: PHASE3. Conditions: Agitated Delirium, Delirium Confusional State, Delirium in the Intensive Care Unit, Hyperactive Delirium

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07395050: Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes

    Sponsor: City of Hope Medical Center. Phase: EARLY_PHASE1. Conditions: Stage 3 Type 1 Diabetes

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05967468: Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

    Sponsor: Baylor College of Medicine. Phase: NA. Conditions: Obsessive-Compulsive Disorder in Children, Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Obsessive-Compulsive Disorder in Adolescence, Generalized Anxiety Disorder, Separation Anxiety, Panic Disorder, Panic Disorder With Agoraphobia, Panic Attacks

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05849168: High-Intensity Interval Training to Improve Symptoms of Deployment-Related Respiratory Disease

    Sponsor: University of Colorado, Denver. Phase: NA. Conditions: Occupational Exposure

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03593317: Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

    Sponsor: Hospices Civils de Lyon. Phase: PHASE2. Conditions: Arrhythmogenic Right Ventricular Dysplasia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07324291: Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients

    Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: . Conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Carbapenem-resistant Enterobacterales

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07426991: Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

    Sponsor: Heinrich-Heine University, Duesseldorf. Phase: . Conditions: Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis, Fatigue Syndrome, Chronic, Sleep Disorders

    full page →ctgov ↗
    ← prev
    page 29 of 102
    next →